Home › Trials › NCT07311850

Once-weekly MET097 for adults with overweight or obesity

Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)

Phase 3 Interventional Pfizer · NCT07311850

This trial will test whether a once-weekly injection called MET097 helps adults with obesity or overweight (without diabetes) lose weight and is safe.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment3500 (estimated)
Ages18 Years to 99 Years
SexAll
SponsorPfizer Industry-sponsored
Locations196 sites (Scottsdale, Arizona and 195 other locations)
Trial IDNCT07311850 on ClinicalTrials.gov

What this trial studies

Adults meeting BMI criteria (≥30 kg/m2, or 27–<30 kg/m2 with at least one weight-related comorbidity) will receive either once-weekly injectable MET097 or matching placebo for up to 84 weeks. The primary efficacy endpoint is measured after 64 weeks of treatment, with additional assessments at 84 weeks and safety monitoring throughout. Key exclusions include any form of diabetes, recent large weight change, personal or family history of medullary thyroid carcinoma or MEN-2, recent pancreatitis, or active symptomatic gallbladder disease. The trial is conducted at multiple clinical research sites in the United States and collects both weight and safety outcome data.

Who should consider this trial

Good fit: Adults with BMI ≥30 kg/m2 or BMI 27.0–<30.0 kg/m2 plus at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) who do not have diabetes and meet other screening requirements are ideal candidates.

Not a fit: People with any form of diabetes, recent large weight changes, a personal or family history of medullary thyroid carcinoma or MEN-2, recent pancreatitis, or active symptomatic gallbladder disease are not likely to be eligible or benefit from participation.

Why it matters

Potential benefit: If successful, MET097 could offer an effective once-weekly injectable option to help people with obesity or overweight lose clinically meaningful weight and improve weight-related health problems.

How similar studies have performed: Other once-weekly injectable medications for weight management (for example GLP-1 receptor agonists) have shown substantial weight loss in similar populations, so this approach builds on earlier successful therapies.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to \<30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Exclusion Criteria:

* Have any form of diabetes
* Have a self-reported body weight change \> 5 kg (11 pounds) within 3 months prior to Screening
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease

Where this trial is running

Scottsdale, Arizona and 195 other locations

+146 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Obesity and Overweight
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.